Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target

Immunotherapy of PD-L1/PD-1 blockage elicited impressive clinical benefits for cancer treatment. However, the relative low response and therapy resistance highlight the need to better understand the molecular regulation of PD-L1 in tumors. Here, we report that PD-L1 is a target of UFMylation. UFMyla...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Junzhi, Ma, Xiaohe, He, Xingrui, Chen, Beiying, Yuan, Jiao, Jin, Zhemin, Li, Lijing, Wang, Zhiguo, Xiao, Qian, Cai, Yafei, Zou, Yongkang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2023
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089188/
https://www.ncbi.nlm.nih.gov/pubmed/36893266
http://dx.doi.org/10.1073/pnas.2215732120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089188/
https://www.ncbi.nlm.nih.gov/pubmed/36893266
http://dx.doi.org/10.1073/pnas.2215732120

Ejemplares similares